Category Archives: Stem Cell Research

Valencia, Spain (PRWEB) June 24, 2014 Today at Cell Science-2014 in Valencia, Spain, Dr. James L. Sherley, Director of Bostons Adult Stem Cell Technology Center, LLC, announced the issue of another significant patent to the companys growing portfolio of adult tissue stem cell intellectual property. The new patent issued today (U.S. Patent and Trademark Office No. 8,759,098) protects a method for producing induced pluripotent stem cells (iPSCs) with a single non-genetic agent. Director Sherley made the announcement at the conclusion of his keynote address at the 4th Annual World Congress on Cell Science and Stem Cell Research. After discussing unique aspects of adult stem cells that are often overlooked, he highlighted a proposed connection between adult stem cells and iPSCs that was the basis for the newly patented biotechnology. iPSCs are currently the subject of intense biological and biomedical research. These artificially produced stem cells provide the research capabilities of human embryonic stem cells (hESCs). But since their production does not involve human embryos, iPSCs do not pose ethical concerns. However, because of their genetic defects and propensity for forming tumors, also like hESCs, it is unlikely that iPSCs will ever be of sufficient quality and safety for use in … Continue reading →

4th World Congress on Cell Science Stem Cell Research The OMICS Group Conferences' 4thWorld congress on Cell Science Stem Cell Research deliberates on the broader areas of Evolution of cancer, Tumorogenesis, R... By: omicsgroup incorporation … Continue reading →

Cell Science Stem Cell Research Relevant conference The OMICS Group Conferences' 4thWorld congress on Cell Science Stem Cell Research deliberates on the broader areas of Evolution of cancer, Tumorogenesis, R... By: omicsgroup incorporation … Continue reading →

Stem Cell Research | GIOSTAR Don Meredith discusses the bull market cycle and advises on whether to buy or sell during this time. Deven Patel, CEO Co-Founder of Giostar, explains his S... By: Craig Sewing … Continue reading →

PUBLIC RELEASE DATE: 19-Jun-2014 Contact: David McKeon DMcKeon@nyscf.org 212-365-7440 New York Stem Cell Foundation NEW YORK, NY (June 18, 2014) Induced Pluripotent Stem Cells (iPS) hold enormous potential to unravel the mechanisms of human illness and to develop new therapeutics. Until now, there has been no easily searchable database for investigators to find and share these important resources. This has been a major obstacle to the implementation of iPS technology. Recognizing the research potential of shared iPS cell lines, the New York Stem Cell Foundation (NYSCF) Research Institute and the eagle-i Network will make NYSCF iPS cell lines and related information available to the public on a user-friendly, web-based, searchable database. The database (called the Induced Pluripotent Stem Cell database) will help scientists find valuable resources, enabling collaboration, preventing duplicative work, and ultimately accelerating research. NYSCF and eagle-i will establish an open access repository of information on large numbers of iPS cell lines. eagle-i will display information as linked open data, enabling discovery by any third party search engine. NYSCF derives hundreds of iPS cell lines from skin samples of patients with a wide variety of diseases using the NYSCF Global Stem Cell ArrayTM technology, an automated platform for high-throughput … Continue reading →

PUBLIC RELEASE DATE: 19-Jun-2014 Contact: Mary Beth O'Leary moleary@cell.com 617-397-2802 Cell Press Stroke is a leading cause of death and disability in developed countries, and there is an urgent need for more clinically effective treatments. A study published by Cell Press June 19th in Stem Cell Reports reveals that simultaneous transplantation of neural and vascular progenitor cells can reduce stroke-related brain damage and improve behavioral recovery in rodents. The stem cell-based approach could represent a promising strategy for the treatment of stroke in humans. "Our findings suggest that early cotransplantation treatment can not only replace lost cells, but also prevent further deterioration of the injured brain following ischemic stroke," says senior study author Wei-Qiang Gao of Shanghai Jiaotong University. "With the development of human embryonic and induced pluripotent stem cell technology, we are optimistic about the potential translation of our research into clinical use." The most common kind of stroke, known as ischemic stroke, is caused by a blood clot that blocks or plugs a blood vessel in the brain. Although a medicine called tissue plasminogen activator can break up blood clots in the brain, it must be given soon after the start of symptoms to work, and there are … Continue reading →

VANCOUVER, British Columbia--(BUSINESS WIRE)--The latest advances in innovative technologies designed to streamline the entire stem cell research workflow from pluripotent cell engineering, culturing, differentiation and characterization to cryopreservation and storage will be showcased this week during the 12thannual International Society for Stem Cell Research (ISSCR) meeting (Thermo Scientific booth #628, Life Technologies booth #829). Thermo Fisher Scientific will host a series of customer and thought leader presentations on topics ranging from the use of Sendai virus reprogramming technology for rapid development of human induced pluripotent stem cells (iPSC) for drug development applications, to industrializing pluripotent stem cells and novel platforms for culturing cells in suspension. The speakers will share new innovations being applied in labs at Harvard University, Cedar-Sinai Medical Center and Saitama Medical University. Access to leading-edge tools that are designed to seamlessly work in combination with each other is critical for our customers to drive new discoveries, said Chris Armstrong, Ph.D., vice president and general manager, cell biology, for Thermo Fisher. Were proud to offer a deep portfolio of technologies that addresses the entire pluripotent stem cell research continuum to enable novel applications in drug discovery and human disease studies. New product innovations at ISSCR this year include: … Continue reading →

PUBLIC RELEASE DATE: 19-Jun-2014 Contact: Shaun Mason smason@mednet.ucla.edu 310-206-2805 University of California - Los Angeles UCLA researchers led by Dr. Brigitte Gomperts have discovered the inner workings of the process thought to be the first stage in the development of lung cancer. Their study explains how factors that regulate the growth of adult stem cells that repair tissue in the lungs can lead to the formation of precancerous lesions. Findings from the three-year study could eventually lead to new personalized treatments for lung cancer, which is responsible for an estimated 29 percent of U.S. cancer deaths, making it the deadliest form of the disease. The study was published online on June 19 in the journal Stem Cell. Gomperts, a member of the UCLA Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research and the UCLA Jonsson Comprehensive Cancer Center, collaborated with Manash Paul and Bharti Bisht, postdoctoral scholars and co-lead authors of the study. Adult stem cells in lung airways are present specifically to repair the airways after injury or disease caused by smoking, pollution, viruses or other factors. Gomperts and her team found that this reparative process is tightly regulated by molecules called reactive oxygen species, … Continue reading →

San Francisco, California (PRWEB) June 23, 2014 The global market for stem cells is expected to reach USD 170.15 billion by 2020, according to a new study by Grand View Research, Inc. Growing prevalence of chronic diseases such as cardiovascular and liver disease, diabetes and cancer coupled with the presence of high unmet medical needs in these disease segments is expected to drive market growth during the forecast period. Moreover, increasing government support pertaining to funding R&D initiatives and the growing demand for medical tourism and stem cell banking services is expected to boost the demand for stem cells over the next six years. The future of this market is expected to be driven by opportunities such as the growing global prevalence of neurodegenerative diseases, increasing demand for contract research outsourcing services and the substitution of animal tissues by stem cells. The stem cells technology market was valued at USD 12.88 billion in 2013 and is expected to grow at a CAGR of over 12.0% during the forecast period. This market was dominated by the cell acquisitions technology segment in terms of share in 2013 owing to the fact that this technology serves as the foremost step to process involving … Continue reading →

PUBLIC RELEASE DATE: 17-Jun-2014 Contact: Amanda Szabo aszabo@hematology.org 202-552-4914 American Society of Hematology (WASHINGTON, June 17, 2014) New research, published online today in Blood, the Journal of the American Society of Hematology, suggests that the diversity of bacteria in the gastrointestinal tract of patients receiving stem cell transplants may be an important predictor of their post-transplant survival. A healthy gastrointestinal tract contains a balanced community of microorganisms (known as microbiota), largely comprised of "friendly" bacteria that aid digestion and are important to immune system function. When this community of microbes is compromised, the microbiota may become less diverse, and the body becomes more susceptible to certain diseases. Previous studies have shown that the intensive treatment given to individuals receiving a stem cell transplant from a healthy donor (known as an allogeneic stem cell transplant or SCT) can destroy a significant portion of the recipients' gut microbiota and reduce its overall diversity. Disturbances of the gut microbiota have been shown to be correlated with post-transplant complications such as bloodstream infections and graft-versus-host disease. "While the link between gut microbiota and complications in allogeneic SCT has been previously established, until this point it has remained unclear whether the gut bacteria of transplant … Continue reading →